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Topic Relevance by Timeline 
Summary 
● Imaging contrast agents, administered intravenously, are diverse, can be used for diagnos-
tic and therapeutic purposes, and have specific regulatory requirements and development 
considerations.  
● Collaborative relationships between industry and academia may provide the best approach 
for the development of these agents.  
● Additional opportunities for development and commercialization include software specific 
for the analysis of contrast-enhanced examinations. 
● There are special considerations for each class of imaging contrast agents with regards to 
market growth and potential avenues for future development.  
Introduction 
Contrast agents for diagnostic imaging—including computed tomography (CT), magnetic reso-
nance imaging (MRI), ultrasound (US), and nuclear medicine/positron emission tomography 
(NM/PET)—are crucial for clinical diagnosis, monitoring of treatment response, and functional 
evaluation. According to projections, the global market for biologic imaging agents is estimated 
to grow 10.6% (from $14.4 billion to $23.9 billion) between 2017 and 2022 (Agdeppa and Spilker). 
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DEVELOPMENT OF INTRAVENOUS CONTRAST AGENTS 
Therefore, to capitalize on this growing market, an understanding of the specific processes for the 
development and commercialization of these products is warranted.  
 
Figure 1. Global Market Projections of Imaging Agents. 
 
 
Legend: Blue bars signify agents in the year 2016. Orange bars signify agents in the year 2017.  
Gray bars signify predictions of agents in 2022. 
Interests of Potential Developers 
Potential developers include members of the industry, academia, and collaborative partnerships 
between the two entities. Diagnostic imaging agents are generally less toxic than interventional 
drugs and many are widely used, thus saturating the existing market and deterring investigators 
from exploring new agents and approaches. Despite the large quantities of imaging agents 
administered clinically, the relatively low reimbursement rates contribute to low profit margins, 
which generally deters industry partners from exploring this category of drug development. 
Notable exceptions exist, however, such as the recent acquisition of an amyloid PET radiotracer 
company for nearly $300 million, with an additional $500 million based on regulatory/commercial 
milestones, by Eli Lilly & Company, a global pharmaceutical company.  Furthermore, when 
utilized for therapeutic or interventional indications, the large initial investment is offset by the 
high financial reward, which is appealing to these companies. Academic interests include novel 
imaging approaches and improving the diagnosis and treatment of patients, but the costs associated 
with Phase 1 and Phase 2 clinical trials create a barrier for clinical translation in the academic 
setting (Joshi). Therefore, collaborative partnerships between academia and pharmaceutical 
companies may offer the best opportunity to mitigate these barriers in development and maximize 
potential benefits (see the chapter “Forming and Maintaining Meaningful Partnerships Between 
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Academic Scientists and Corporations”). One such method of collaboration that appeals to the 
interests of both industry and academia is “theranostics” where the contrast agent is used both for 
diagnosis and either therapy or guiding intervention to allow the personalized treatment of patients. 
There has been a growing interest on the part of the National Institutes of Health (NIH) to fund 
this type of research. For example, theranostic nanomedicine is a specific subsection within the 
NIBIB, and theranostics is now listed as the “highest priority challenge topic” for NIAMS. 
Development in the United States 
Many available imaging contrast agents for CT and MRI are long established and widely used. 
Emerging agents have also recently been introduced in the United States, particularly in the realm 
of US and NM/PET imaging. This juxtaposition of different classes of imaging agents highlights 
the complexity associated with the expansion and development of imaging contrast agents, which 
hinges upon either the improvement of existing agents or the development of novel imaging drugs. 
The Food and Drug Administration (FDA) provides guidance in this process (Office of the Com-
missioner; Center for Drug Evaluation and Research, “Developing Medical Imaging Drug and 
Biological Products Part 1: Conduc”). To summarize their provided materials, if a contrast agent 
is currently approved, it can be approved for use with a class of devices (e.g., CT, MRI, US) (Table 
1), but if the specific contrast agent requires certain software for interpretation, it may require 
approval as a combination product, and the FDA Office of Combination Products can serve as a 
valuable resource. Imaging software has traditionally been approved independently of contrast 
media and often as a component of imaging systems. However, the continued growth of imaging 
agents for NM/PET, which may require specialized software packages for analysis and 
interpretation, may necessitate classification as combination products. 
Non-Radiolabeled Agents 
For non-radiolabeled agents, 501(k) submissions are required for adding approved contrast agents 
to a device, or for a new indication; if the proposed use is different from current labeling, New 
Drug Application (NDA) supplements are required (see the chapter “FDA Device Regulation: 
510(k), PMA”). These processes are complicated by the fact that imaging contrast agents are often 
approved only for essential indications but frequently are clinically used “off-label,” particularly 
in children and for MRI (Hung).  
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Table 1. Quantification of Agents Based on Type and Modality. 
 
  
  
Development of novel non-radiolabeled contrast-based media requires extensive safety data and 
confirmation. Approval requirements include a clinical safety assessment, which provides preclin-
ical data on dose and volume, the effects of drug accumulation, and underlying properties. In this 
process, non-radiolabeled contrast agents can almost always be classified as “therapeutic agents” 
in FDA materials, as a large dose is required for adequate administration. As these agents are 
typically used in high doses at a limited number of single-dose administrations, long-term use 
repeat-dose safety trials are generally not required for approval. The contrast agent should 
demonstrate added benefit to one of the following specific categories: structure delineation, 
disease/pathology detection or assessment, function, physiologic or biochemical assessment, 
diagnostic or therapeutic patient management, or multiple indications. While this seems 
straightforward, there are special requirements for combination products, and guidance from the 
FDA Office of Combination Products is particularly important during this process (301-427-1934; 
combination@fda.gov; www.fda.gov/CombinationProducts/default.htm). 
Radiolabeled Agents 
Radiolabeled imaging contrast agents, used for NM/PET indications, have a more complicated 
developmental pathway as they are composed of more diverse chemical compounds and contain 
radioactive materials. PET-specific agents will be briefly discussed here to illustrate differences 
from non-radiolabeled agents (Josephson and Rudin). For one, the FDA requires an NDA or an 
Abbreviated New Drug Application (ANDA) for all PET drugs. As doses administered are typi-
cally in the microdose range, extensive pharmacology and toxicology safety information is often 
not necessary, and the FDA encourages pooling of existing data from multiple sources. Particularly 
for radioactive agents used for research, depending on the intent of the research (clinical trial 
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versus basic science), Investigational New Drug (IND) approvals may be needed. The use of mi-
crodose agents may also allow more expedited approaches for early-stage research, including filing 
an Exploratory IND (eIND) application and going through the Radioactive Drug Research 
Committee (RDRC), which is handled through a local institutional RDRC, whose action is 
reviewed and monitored by the FDA. Some agents may be considered medical devices—for 
example, Yttrium-90-labeled microspheres for liver tumor treatment—and may be eligible for an 
Investigational Device Exemption (IDE). 
  
Lastly, reimbursement potential from insurance companies and from the Center for Medicare and 
Medicaid Services (CMS) should be considered during the development process, as this infor-
mation may inform investment decisions and research processes. Imaging contrast agents typically 
are billed as drugs required for an imaging study (typically CT and MRI) or as an add-on charge 
to a clinically indicated examination (US contrast agents). NM/PET agents usually fall into the 
former category but may also be billed as specific treatment procedures for radionuclide therapy. 
Currently, a specific mechanism exists through CMS—the coverage with evidence development—
to demonstrate the impact and medical utility of an FDA-approved agent to assure insurance 
coverage while conducting a clinical research study and to encourage future coverage by all 
insurers. Once such example is the “Imaging Dementia—Evidence for Amyloid Scanning” 
(IDEAS) study, which obtained CMS coverage for amyloid PET examinations while investigating 
the medical necessity and patient benefits. Ultimately, especially in light of ongoing changes to 
regulatory and reimbursement requirements, discussion with the FDA and possibly the CMS early 
in the developmental process may be worthwhile.  
Intellectual Property 
As discussed previously, the generally low financial yield with contrast agent development en-
courages developers to more closely guard their intellectual property (see the chapters “Intellectual 
Property: Ownership and Protection in a University Setting” and “Intellectual Property: 
Commercializing in a University Setting”). However, this approach can still be cost-prohibitive 
for licensors of niche imaging contrast agents with a small market size. Therefore, partnerships 
between academia and the industry should be considered, as complementary expertise and 
infrastructure can be mutually beneficial in drug development by allowing the merging of 
resources, including intellectual property. For example, the pooling of patents under one primary 
sponsor/institution streamlines regulatory processes and provides greater flexibility in develop-
ment. Collaboration between pharmaceutical and imaging companies also improves the cost-
effectiveness of drug development by allowing the coupling of therapeutics with molecular 
imaging (Kohli et al.). This approach streamlines the potential development of targeted therapy, 
as exemplified by novel Alzheimer’s imaging agents, where the clinical benefit lies with coupled 
treatment agents rather than solely with diagnosis. Lastly, collaboration with industry partners and 
the sharing of intellectual property allows coordination of multi-institutional investigations, which 
can increase patient access, subject accrual, and breadth of experience in different clinical settings, 
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which ultimately can accelerate drug development and regulatory approval. In recognition of these 
beneficial relationships, specific funding mechanisms for academic-industrial partnerships exist 
through various NIH institutes, such as the National Center for Advancing Translational Sciences 
(NCATs). 
Patents 
Development of imaging contrast agents is typically under broad existing patents specific to the 
type of agent. For example, current patents for “contrast agent and its use for imaging” 
(WO2014041150A1), “contrast agents for diagnostic imaging” (WO1995028179A1), and “con-
trast agents and methods for preparing contrast agents” (US8173105B2) have been granted. This 
approach is different for molecular imaging agents, for which patents are specific to the type and 
structure of the molecule. These patents include “labeled molecular imaging agents, methods of 
making and methods of use” (US20100272641A1), “molecular imaging agents” 
(US20110293519A1), and “molecular imaging contrast agents and uses thereof” 
(WO2015134671A1). Innovative development of imaging contrast agents will require either a new 
patent or licensing under previously established patents. Evaluating the current patents and the 
breadth of coverage will inform this process. 
Software Development 
One unique characteristic of some imaging contrast agents is the potential for development of 
specific software for analysis and interpretation of imaging studies (Lusic and Grinstaff). For 
example, as development and use of ultrasound contrast agents (UCAs) have expanded in the 
United States, clinical need for quantitative analysis of UCA kinetics for perfusion assessment has 
prompted the exploration of specific software packages. Some products that perform time-intensity 
curve analysis have been developed and licensed by vendors, integrated into the US system, and 
marketed as add-on purchases to institutions (i.e., QLAB, and Philips Healthcare North America). 
Others are stand-alone software packages that are compatible with many different US systems, 
such as VueBox® (Bracco Diagnostics) and SonoLiver® (TomTec Imaging Systems). Develop-
ment and use of these technologies may require material transfer agreements (MTAs). 
 
As a corollary to independent software development, many vendors have innovation arms that 
sponsor partnerships with developers, typically in the form of venture capital. However, in addition 
to financial investment and commercialization resources, these relationships provide developers 
with access to global infrastructure and networks. Engaging in these partnerships offers multiple 
opportunities for growth and development of software technology. Ultimately, collaborative 
efforts with industry and manufacturing partners throughout the process may be beneficial to both 
parties.    
 
6https://repository.upenn.edu/ace/vol1/iss3/12
 
 
DEVELOPMENT OF INTRAVENOUS CONTRAST AGENTS 
Additional factors related to imaging datasets and analysis, including data storage and protection 
and computer learning algorithms (artificial intelligence), are worth mentioning, as they warrant 
attention from software developers and vendors and provide another unique market opportunity 
for potential commercialization. However, these topics are expansive, apply broadly to all imaging 
studies regardless of contrast administration, and are outside the scope of this review. Current 
relevant literature covers these issues in greater detail (Mayo et al.; Maier and Schreiber). 
Special Considerations by Agent Class 
Iodine-based contrast agents 
CT and fluoroscopic angiography—widely used imaging technologies—require the use of iodine-
based contrast agents for diagnosis and interventional guidance (Moek et al.). These agents are 
also used as enteric contrast agents for fluoroscopy and CT, however, despite higher profit margins 
in this capacity, there has been a loss of market share due to decreased use. The market is domi-
nated by a few reliable agents, with limited growth for comparable agents.  However, these agents 
are limited by their renal excretion and relative contraindication in patients with kidney problems 
such as renal insufficiency or dialysis requirements. Therefore, there is a current void in the market 
for contrast agents that avoid renal toxicity, which offers a potential target for future developers 
(Pierre et al.). 
  
Gadolinium-based contrast agents (GBCAs) for Magnetic Resonance Imaging 
The MRI contrast agents most commonly utilized clinically are composed of gadolinium polymers. 
These contrast agents are crucial for many imaging indications including identification and 
visualization of neoplasm and metastatic disease, degenerative disease, infection and 
inflammation, stroke, and musculoskeletal imaging. There are currently 11 FDA-approved 
GBCAs for MRI, and the current market growth has focused upon the expansion of indications of 
current agents (Center for Drug Evaluation and Research, “New Warnings for Gadolinium-Based 
Contrast Agents (GBCAs) for MRI”). In addition to the concerns of nephrogenic systemic fibrosis, 
rarely seen after administration of gadolinium-based agents in patients with renal disease, 
theoretical concerns regarding gadolinium deposition, seen primarily with microcyclic agents with 
repeated administration, have dominated the scientific discourse. This theoretical concern has cul-
minated in the recent safety announcement from the FDA alerting patients to the potential for 
gadolinium retention with these agents (Center for Drug Evaluation and Research, “New Warnings 
for Gadolinium-Based Contrast Agents (GBCAs) for MRI”). Therefore, there is great potential for 
the development of additional agents, such as macrocyclic agents and those not renally excreted, 
that would avoid these risks.   
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Superparamagnetic Iron Oxide (SPIO) contrast agents for Magnetic Resonance 
Imaging 
SPIOs are within an emerging class of imaging contrast agents; one SPIO particle formulation has 
obtained clinical approval in the United States for imaging (Feridex IV®, Berlex Laboratories), 
while a second SPIO formulation has been approved by the FDA for the treatment of iron-
deficiency anemia but is being investigated as an imaging agent in the research setting 
(Feraheme®, AMAG Pharmaceuticals) (Reimer and Vosshenrich). Several additional SPIO agents 
are available in foreign countries and under development. These contrast agents undergo phago-
cytosis after intravenous administration, and the iron components are ultimately incorporated into 
the normal iron pool of the body and have no risk of nephrogenic systemic fibrosis (Spampinato 
et al.; Wáng and Idée), thus avoiding some concerns with GBCAs outlined above. Despite these 
potential comparative benefits, development of SPIO agents has been hampered by the relatively 
higher rates of hypersensitivity reactions and the decreased sensitivity in evaluating the disease 
process when compared to GBCAs. Therefore, even though SPIO agents are a promising category 
for imaging agent development, further dosing and safety data are warranted with both current and 
future agents. While the development cost is high, the anticipated market volume for these agents 
is small, thus limiting interest from pharmaceutical companies. Lastly, for those SPIO agents 
without current approval for imaging, one should consider the concerns regarding lack of insurance 
reimbursement. 
  
Microbubble contrast agents for contrast-enhanced ultrasound 
Ultrasound contrast agents (UCAs) are relatively new in the US market and have shown benefit in 
diagnostic imaging. With an excellent safety profile and use with US, a noninvasive radiation-free 
imaging modality, UCAs have been gaining traction in clinical practice. Available FDA-approved 
diagnostic imaging agents include Optison® (GE Healthcare), Sonovue®/Lumason® (Bracco 
Diagnostics), and Definity® (Lantheus Medical Imaging). While rare immune-mediated sensitiv-
ity reactions have been reported, general safety has been established. Targets for development 
include exploring methods of quantification and functional imaging and the delivery of therapeutic 
agents. 
  
Radiolabeled agents for Positron Emission Technology (PET) or Single-Photon 
Emission Computed Tomography (SPECT) 
Imaging contrast agents used in nuclear medicine, including PET or SPECT, are utilized for cancer 
diagnosis, treatment monitoring, endocrine disorders, and cardiology applications. Relatively new 
indications include the diagnosis and assessment of neurologic disorders. Commonly utilized 
agents include fluorodeoxyglucose or FDG (glucose metabolism and disease 
detection/monitoring), Iodine-123 and Iodine-131 (thyroid disease detection/treatment), 
Technetium-99m-Sestamibi (myocardial perfusion), and Ioflupane-123 (DaTSCAN for detection 
of Parkinson’s Disease). The impetus for growth in this group is for new disease-specific agents 
and/or agents focused on specific biologic processes such as neurodegeneration. As these contrast 
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agents are developed for the targeted detection of disease, and often have a more facile translation 
pathway, there is a huge potential for relatively easy translation to therapeutic agents. This includes 
theranostics, where radiolabeled compounds, including small molecules, peptides, and antibodies, 
may diagnose and treat a disease simultaneously (Wang).  
Pediatric Considerations 
As briefly discussed above, imaging contrast agents are not always evaluated in children and sub-
sequently they are not specifically approved for use in pediatric patients. In many situations these 
contrast agents are instead used “off-label” as this is considered the standard of care. This practice, 
while beneficial clinically, introduces challenges for researchers and developers in investigating 
the safety and efficacy of these agents in children. Furthermore, research ethicists and institutional 
review boards consider children a special population by virtue of their inability to provide 
informed consent. This appropriate classification imparts additional protections upon children, as 
well as increased regulations and requirements in regards to research methods and processes.  
Therefore, industry partners are generally reluctant to pursue FDA approval for imaging contrast 
agents in children. In turn, there is less market competition, which offers ample opportunities for 
growth and development of contrast agents approved for use in pediatric patients for those 
companies and institutions willing to investigate this further. Again, collaborative partnerships 
between industry and academia can help mitigate some of these concerns to allow maximal benefit 
for pediatric patients, investigators, and developers (see the chapter “Forming and Maintaining 
Meaningful Partnerships Between Academic Scientists and Corporations”). 
Obtaining Expert Advice 
Development of imaging contrast agents may require the help and guidance of the FDA, as dis-
cussed, as well as institutional technology transfer offices (see the chapter “Working with the 
University Technology Transfer Office”). These resources should be contacted and included early 
in the process to ensure appropriate development. As imaging contrast agent development is best 
suited for industry-academia collaboration, industry contacts with device manufacturers may 
prove beneficial. Discussion with the technology transfer office can be crucial in this process, 
especially as an academic faculty member is considering presenting results at scientific 
conferences (which may invalidate future patents if not handled properly). Furthermore, conflict 
of interest may limit future work by the academic faculty member, and disclosure of information 
with an industry partner may provide them with a competitive advantage if not properly covered 
by a nondisclosure agreement (NDA). 
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Conclusion 
Intravenous contrast agents for diagnostic imaging are a large and growing market in the United 
States, with vast opportunities for developers. Success in development and commercialization will 
likely depend on collaborative relationships between industry and academia, with consideration of 
the special circumstances related to these agents described in this chapter.  
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